Alternative administration of camptothecin analogues.
In order to improve the therapeutic index of camptothecin (CPT) analogues, alternative administration of CPT analogues is being evaluated. Topotecan, irinotecan, rubitecan, lurtotecan and 9-aminocamptothecin have been administered orally with response rates equivalent to that seen after intravenous administration, where applicable. Oral availability and administration of some of the newer CPT analogues, including diflomotecan (BN80915) and grimatecan (ST1481), have also shown promising results. Aerosolisation of liposomal 9-nitrocamptothecin has been studied in patients with advanced malignancies involving the lung, demonstrating systemic antitumour activity. Intrathecal administration of topotecan has been studied in children with refractory neoplastic meningitis. It is well tolerated and associated with some antitumour activity. Intraperitoneal administration of topotecan as consolidation therapy in patients with ovarian cancer has shown promising results. Transdermal administration of rubitecan has been studied in mice. So far, no CPT has been approved for an alternative route of administration.
Glaberman
Ursa
U
University of New Mexico Cancer Research and Treatment Center, Albuquerque, 87131, USA.
Rabinowitz
Ian
I
Verschraegen
Claire F
CF
D000279:Administration, Cutaneous; D000280:Administration, Inhalation; D000284:Administration, Oral; D000336:Aerosols; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D002166:Camptothecin / Q000008:administration & dosage* / Q000031:analogs & derivatives; D006801:Humans; D007273:Injections, Intramuscular; D007274:Injections, Intraperitoneal; D007278:Injections, Spinal; D008081:Liposomes
D000336:Aerosols; D000972:Antineoplastic Agents, Phytogenic; D008081:Liposomes; D002166:Camptothecin